English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAbstract: https://www.acpjournals.org/doi/10.7326/M23-2447 URL goes live when the embargo lifts ACP leaders have strong words for pharmaceutical and other health care companies that are challenging the implementation of the Medicare prescription drug price negotiation program. So far, these businesses have spent approximately $400 million challenging the program in U.S. courts. ACP, along with other medical societies, is pushing back.
In a new commentary published in Annals of Internal Medicine, ACP’s Executive Vice President and Chief Executive Officer Darilyn V. Moyer, MD, MACP and Senior Vice President and Chief Advocacy Officer Shari M. Erickson, MPH express strong support for the Inflation Reduction Act. The bill was signed into law last year, providing the U.S. Secretary of Health and Human Services with the authority to negotiate the prices for a set number of drugs, with implementation of those decreased prices in 2026. While the first 10 drugs in the Medicare Part D program were recently named, this is only a starting point and more needs to be done, ACP leaders say. Many patients still face what ACP calls a “Sophie’s choice,” or having to decide between purchasing their prescription medications or other life-sustaining necessities. For those patients, ACP vows to fight.
“ACP is resolute in its policy to put patients above pharmaceutical interests and will continue to work relentlessly to ensure that the program moves forward,” said Dr. Moyer. “Imagine how much of that pharmaceutical money could have gone to help persons who were so desperate to cover health care costs and the necessities of life that they went without or resorted to crowdsourcing campaigns. Enough is enough!”
Media contacts: For an embargoed PDF, please contact Angela Collom at [email protected]. To speak with someone from ACP, please contact Jacquelyn Blaser at [email protected].
